The price-to-earnings ratio for Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is above average at 18.01x. The 36-month beta value for CPRX is also noteworthy at 0.78. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CPRX is 105.85M, and at present, short sellers hold a 5.76% of that float. The average trading volume of CPRX on December 13, 2024 was 950.84K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CPRX) stock’s latest price update
The stock of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has decreased by -1.09 when compared to last closing price of 21.34.Despite this, the company has seen a loss of -4.15% in its stock price over the last five trading days. zacks.com reported 2024-12-09 that Catalyst (CPRX) reported earnings 30 days ago. What’s next for the stock?
CPRX’s Market Performance
Catalyst Pharmaceuticals Inc (CPRX) has experienced a -4.15% fall in stock performance for the past week, with a -7.43% drop in the past month, and a 3.26% rise in the past quarter. The volatility ratio for the week is 2.46%, and the volatility levels for the past 30 days are at 3.26% for CPRX. The simple moving average for the past 20 days is -2.35% for CPRX’s stock, with a 16.26% simple moving average for the past 200 days.
Analysts’ Opinion of CPRX
Many brokerage firms have already submitted their reports for CPRX stocks, with Stephens repeating the rating for CPRX by listing it as a “Overweight.” The predicted price for CPRX in the upcoming period, according to Stephens is $35 based on the research report published on November 18, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see CPRX reach a price target of $27. The rating they have provided for CPRX stocks is “Buy” according to the report published on March 14th, 2024.
BofA Securities gave a rating of “Buy” to CPRX, setting the target price at $23 in the report published on March 07th of the current year.
CPRX Trading at -2.12% from the 50-Day Moving Average
After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.03% of loss for the given period.
Volatility was left at 3.26%, however, over the last 30 days, the volatility rate increased by 2.46%, as shares sank -2.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.04% upper at present.
During the last 5 trading sessions, CPRX fell by -4.27%, which changed the moving average for the period of 200-days by +31.50% in comparison to the 20-day moving average, which settled at $21.61. In addition, Catalyst Pharmaceuticals Inc saw 25.56% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CPRX starting from Miller Steve, who sale 50,000 shares at the price of $21.93 back on Dec 10 ’24. After this action, Miller Steve now owns 686,996 shares of Catalyst Pharmaceuticals Inc, valued at $1,096,350 using the latest closing price.
Miller Steve, the Officer of Catalyst Pharmaceuticals Inc, proposed sale 50,000 shares at $21.93 during a trade that took place back on Dec 10 ’24, which means that Miller Steve is holding shares at $1,096,333 based on the most recent closing price.
Stock Fundamentals for CPRX
Current profitability levels for the company are sitting at:
- 0.38 for the present operating margin
- 0.82 for the gross margin
The net margin for Catalyst Pharmaceuticals Inc stands at 0.31. The total capital return value is set at 0.26. Equity return is now at value 28.29, with 24.10 for asset returns.
Based on Catalyst Pharmaceuticals Inc (CPRX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 77.74.
Currently, EBITDA for the company is 119.69 million with net debt to EBITDA at -2.28. When we switch over and look at the enterprise to sales, we see a ratio of 4.54. The receivables turnover for the company is 7.9for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.11.
Conclusion
In summary, Catalyst Pharmaceuticals Inc (CPRX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
